BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 7016323)

  • 21. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
    Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
    Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repeated high-dose cyclophosphamide, BCNU and VP-16-213 and autologous bone marrow transplantation in adult acute lymphocytic leukemia in first remission.
    Vellekoop L; Dicke KA; Zander AR; Spitzer G; Verma DS; Keating MM; McCredie KB
    Eur J Cancer Clin Oncol; 1984 May; 20(5):593-9. PubMed ID: 6376130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of high-dose cyclophosphamide plus high-dose etoposide in malignant brain tumors of children followed by autologous bone marrow rescue].
    Hanada R; Inaba T; Yaginuma A; Hayashi Y; Yamamoto K; Nishimoto H; Tsukiyama T
    Gan To Kagaku Ryoho; 1989 Feb; 16(2):263-8. PubMed ID: 2645835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia].
    Ikuta K; Fujioka K; Sumita H; Takahashi H; Sekiguchi H; Kai S; Kajigaya Y; Funabiki T; Sakai H; Matsuyama S
    Rinsho Ketsueki; 1993 May; 34(5):636-42. PubMed ID: 8100284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility of high dose VP 16-213 as single agent or in combination with cyclophosphamide and autologous bone marrow transplantation (ABMT).
    Mulder NH; Meinesz AF; Sleijfer DT; Postmus PE; De Vries EG; Van der Geest S; Orie JL; Vriesendorp R
    Neth J Med; 1984; 27(10):389-92. PubMed ID: 6096742
    [No Abstract]   [Full Text] [Related]  

  • 27. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fractionated total body irradiation and high-dose VP-16 with purged autologous bone marrow rescue for children with high risk relapsed acute lymphoblastic leukemia.
    Schmid H; Henze G; Schwerdtfeger R; Baumgarten E; Besserer A; Scheffler A; Serke S; Zingsem J; Siegert W
    Bone Marrow Transplant; 1993 Dec; 12(6):597-602. PubMed ID: 8136744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine.
    Look AT; Dahl GV; Kalwinsky D; Senzer N; Mason C; Rivera G
    Cancer Treat Rep; 1981; 65(11-12):995-9. PubMed ID: 6170431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study.
    Saez RA; Slease RB; Strnad C; Selby GB; Confer DL; Epstein RB
    Bone Marrow Transplant; 1995 Oct; 16(4):507-14. PubMed ID: 8528165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.
    Reece DE; Nevill TJ; Sayegh A; Spinelli JJ; Brockington DA; Barnett MJ; Klingemann HG; Connors JM; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Fairey RN; O'Reilly SE; Phillips GL
    Bone Marrow Transplant; 1999 Jun; 23(11):1131-8. PubMed ID: 10382952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
    Stein RS; Greer JP; Goodman S; Brandt SJ; Morgan DS; Macon WR; McCurley TL; Wolff SN
    Bone Marrow Transplant; 2000 Feb; 25(3):257-62. PubMed ID: 10673696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide.
    Johny A; Song KW; Nantel SH; Lavoie JC; Toze CL; Hogge DE; Forrest DL; Sutherland HJ; Le A; Nitta JY; Barnett MJ; Smith CA; Shepherd JD; Nevill TJ
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):480-9. PubMed ID: 16545732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
    Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
    Gryn J; Johnson E; Goldman N; Devereux L; Grana G; Hageboutros A; Fernandez E; Constantinou C; Harrer W; Viner E; Goldberg J
    Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia.
    Zander AR; Culbert S; Jagannath S; Spitzer G; Keating M; Larry N; Cockerill K; Hester J; Horwitz L; Vellekoop L
    Cancer; 1987 Mar; 59(6):1083-6. PubMed ID: 3545428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.